Alpha cells, the main source of IL-1β in human pancreas

Journal of Autoimmunity

Volumn 81, Issue , 2017, Pages 68-73

  Anquetil, Florence ^a   Sabouri, Somayeh ^a   Thivolet, Charles ^a   Rodriguez Calvo, Teresa ^a   Zapardiel Gonzalo, Jose ^a   Amirian, Natalie ^a   Schneider, Darius ^a   Castillo, Ericka ^a   Lajevardi, Yasaman ^a   von Herrath, Matthias G ^a,b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Alpha cells; Interleukin 1 ; Pancreas; Type 1 diabetes

Indexed keywords

INTERLEUKIN 1BETA; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CYTOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; PANCREAS; PATHOLOGY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; GLUCAGON-SECRETING CELLS; HUMANS; INTERLEUKIN-1BETA; PANCREAS;

EID: 85015422023     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2017.03.006     Document Type: Article

References (26)

1. Unger, R.H., Orci, L., The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1 (1975), 14–16.
2. Nepom, G.T., Ehlers, M., Mandrup-Poulsen, T., Anti-cytokine therapies in T1D: concepts and strategies. Clin. Immunol. 149 (2013), 279–285.
3. Banerjee, M., Saxena, M., Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus. World J. diabetes 5 (2014), 493–504.
4. Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H.I., Spinas, G.A., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. investig. 110 (2002), 851–860.
5. Dorrell, C., Schug, J., Lin, C.F., Canaday, P.S., Fox, A.J., Smirnova, O., et al. Transcriptomes of the major human pancreatic cell types. Diabetologia 54 (2011), 2832–2844.
6. Boni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D.T., Prazak, R., et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150 (2009), 5218–5229.
7. Donath, M.Y., Boni-Schnetzler, M., Ellingsgaard, H., Halban, P.A., Ehses, J.A., Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol. metabol. TEM 21 (2010), 261–267.
8. Eizirik, D.L., Sammeth, M., Bouckenooghe, T., Bottu, G., Sisino, G., Igoillo-Esteve, M., et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet., 8, 2012, e1002552.
9. Spinas, G.A., Palmer, J.P., Mandrup-Poulsen, T., Andersen, H., Nielsen, J.H., Nerup, J., The bimodal effect of interleukin 1 on rat pancreatic beta-cells–stimulation followed by inhibition–depends upon dose, duration of exposure, and ambient glucose concentration. Acta Endocrinol. 119 (1988), 307–311.
10. Wilson, C.A., Jacobs, C., Baker, P., Baskin, D.G., Dower, S., Lernmark, A., et al. IL-1 beta modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J. Immunol. 144 (1990), 3784–3788.
11. Barral, A.M., Thomas, H.E., Ling, E.M., Darwiche, R., Rodrigo, E., Christen, U., et al. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J. Autoimmun. 27 (2006), 166–173.
12. Moran, A., Bundy, B., Becker, D.J., DiMeglio, L.A., Gitelman, S.E., Goland, R., et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381 (2013), 1905–1915.
13. Dinarello, C.A., Donath, M.Y., Mandrup-Poulsen, T., Role of IL-1beta in type 2 diabetes. Current opinion in endocrinology. diabetes, Obes. 17 (2010), 314–321.
14. Larsen, C.M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J.A., Seifert, B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 (2007), 1517–1526.
15. Larsen, C.M., Faulenbach, M., Vaag, A., Ehses, J.A., Donath, M.Y., Mandrup-Poulsen, T., Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes care 32 (2009), 1663–1668.
16. Marselli, L., Thorne, J., Dahiya, S., Sgroi, D.C., Sharma, A., Bonner-Weir, S., et al. Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS one, 5, 2010, e11499.
17. Boni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J.A., Kerr-Conte, J., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. metabol. 93 (2008), 4065–4074.
18. Welsh, N., Cnop, M., Kharroubi, I., Bugliani, M., Lupi, R., Marchetti, P., et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?. Diabetes 54 (2005), 3238–3244.
19. Maedler, K., Sergeev, P., Ehses, J.A., Mathe, Z., Bosco, D., Berney, T., et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 8138–8143.
20. Sumpter, K.M., Adhikari, S., Grishman, E.K., White, P.C., Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Pediatr. diabetes 12 (2011), 656–667.
21. Aharon-Hananel, G., Jorns, A., Lenzen, S., Raz, I., Weksler-Zangen, S., Antidiabetic effect of Interleukin-1beta antibody therapy through beta-cell protection in the cohen diabetes-sensitive rat. Diabetes 64 (2015), 1780–1785.
22. Mandrup-Poulsen, T., Pickersgill, L., Donath, M.Y., Blockade of interleukin 1 in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6 (2010), 158–166.
23. Wewers, M.D., Dare, H.A., Winnard, A.V., Parker, J.M., Miller, D.K., IL-1 beta-converting enzyme (ICE) is present and functional in human alveolar macrophages: macrophage IL-1 beta release limitation is ICE independent. J. Immunol. 159 (1997), 5964–5972.
24. Zhao, R., Zhou, H., Su, S.B., A critical role for interleukin-1beta in the progression of autoimmune diseases. Int. Immunopharmacol. 17 (2013), 658–669.
25. Yelich, M.R., In vivo endotoxin and IL-1 potentiate insulin secretion in pancreatic islets. Am. J. physiol. 258 (1990), R1070–R1077.
26. Kay, T.W., Dudek, N.L., Graham, K., Estella, E., Angstetra, E., McKenzie, M.D., Allison, J., Thomas, H.E., Cytotoxic T cell mechanisms of beta cell destruction in non-obese diabetic mice. Novartis Found. Symp. 292 (2008), 68–78 discussion -84, 122-9, 202-3.